1. Home
  2. HYPR vs NOTV Comparison

HYPR vs NOTV Comparison

Compare HYPR & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyperfine Inc.

HYPR

Hyperfine Inc.

N/A

Current Price

$1.15

Market Cap

107.9M

Sector

Health Care

ML Signal

N/A

Logo Inotiv Inc.

NOTV

Inotiv Inc.

N/A

Current Price

$0.40

Market Cap

12.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HYPR
NOTV
Founded
2014
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.9M
12.7M
IPO Year
2021
1997

Fundamental Metrics

Financial Performance
Metric
HYPR
NOTV
Price
$1.15
$0.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$1.28
$1.50
AVG Volume (30 Days)
293.1K
564.7K
Earning Date
04-20-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
9.68
49.64
EPS
N/A
N/A
Revenue
$12,890,000.00
$547,656,000.00
Revenue This Year
$5.96
$5.28
Revenue Next Year
$34.43
$5.42
P/E Ratio
N/A
N/A
Revenue Growth
16.84
511.19
52 Week Low
$0.53
$0.25
52 Week High
$2.22
$3.35

Technical Indicators

Market Signals
Indicator
HYPR
NOTV
Relative Strength Index (RSI) 55.78 52.69
Support Level $1.04 $0.26
Resistance Level $1.19 $0.65
Average True Range (ATR) 0.07 0.05
MACD 0.01 0.03
Stochastic Oscillator 73.17 67.59

Price Performance

Historical Comparison
HYPR
NOTV

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: